Skip to main content

Table 1 Clinical and demographic characteristics of 577 patients from 26 studies included in the systematic review

From: Effectiveness of rituximab in neuromyelitis optica: a meta-analysis

Reference (study) Research type Patient No. Sex (F/M) Age (year) AQP4-Ab (+) (case) Duration of disease (years/month) Follow-up (years/month)
Jacob [11] 2008 Retrospective 25 22/3 38(7–65) 11 4.5(0.8–17)y 19(6–40)m
Jarius [14] 2008 Retrospective 4 NC 45(19–59) 4 NC 62(33–144)m
Pellkofer [16] 2011 Prospective 9 8/1 36.1(11.5) 9 11(7.7)y 29.6(14.5)m
Gurdesh [2] 2011 Retrospective 23 21/2 37.1(14.6) 15 114(13–266)m 32.5(7–63)m
Lindsey [26] 2012 Retrospective 8 7/1 37.6(14.4) 4 65.1(53.7)m 39.9(40.7)m
Yang [20] 2013 Retrospective 3 NC 34.3(8.5) 2 9.3(4)y 12.7(0.6)m
Ip [5] 2013 Retrospective 7 6/1 52(22–62) 4 57(40–272)m 24(1–42)m
Ayzenberg [27] 2013 Retrospective 3 3/0 35(7.8) 3 6.7(3.7)y 14.7(15.1)m
Gredler [28] 2013 observational 4 4/0 42.5(15.4) 4 6.2(4.2)y 3.1(2.1)y
Chay [10] 2013 Retrospective 6 4/2 37.8(20.6) 3 NC NC
Longoni [25] 2014 Retrospective 5 4/1 13.7(2.7) 5 3.2(0.3)y 21.5(6.9)m
Kim [23] 2015 Retrospective 100 92/8 43(11) 94 11(5)y 67(9–108)m
Zephir [22] 2015 Retrospective 32 27/5 45(12.1) 28 6.5(1–410)m 28.7(21)m
Weinfurtner [18] 2015 Retrospective 4 3/1 26.5(22.3) 3 6.5(3.1)y 6(1.2)y
Jeong [29] 2015 Retrospective 55 50/5 42(15–68) 52 41.7(2.1–231.5)m 64.7(6.2–99.8)m
Valentino [7] 2016 Retrospective 7 6/1 38.3(16.6) 7 NC 59.4(29.7)m
Annovazzi [1] 2016 Retrospective 76 64/9 46.5(12.5) 53 6(7.2)y 35.6(27)m
Collongues [30] 2016 Retrospective 21 19/2 37.8(15.5) 19 46.9(51.2)m 31(18)m
Zhang [31] 2017 Case-control 31 23/8 42.2(16.9) 15 4.05(2.11)y 27.45(11.68)m
Nikoo [32]2017 RCT 33 29/4 35.33(8.98) 13 6.23(4.29)y > 12 m
Evange. [17]2017 Retrospective 5 5/0 54(10.21) 5 6.8(1.3)y 6.6(0.9)y
Cohen [33] 2017 Prospective 40 33/7 40.2(22–62) 20 40(2–165)m 2y
Tallantyre [34] 2018 Retrospective 5 5/0 36.6(14.5) 5 11.5(9.4)y 3.5(0.2–8.9)y
Yang [15] 2018 Prospective 20 19/1 40.7(11.4) 10 11(0.2–240)m 29(18–40)m
Cabre [35] 2018 Prospective 32 30/2 39.9(12.1) 20 NC 2y
Li [21] 2018 Retrospective 19 16/3 34.8(13.7) 17 3.4(3.4)y 2.5(1.7)y
  1. RCT Randomized clinical trial, AQP4-Ab Aquaporin 4 autoantibody, NC No clear